Merck & Co. is putting down $30 million cash to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset ...

Merck gains preclinical compounds designed to exploit DNA repair defects in difficult to treat cancersNEW HAVEN, Conn., Oct.

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Gov. Kathy Hochul on Tuesday announced a $150 million investment in a new state-of-the-art cell and gene therapy hub to be built on Long Island.

Editas, one of the oldest CRISPR-focused biotechs, is pivoting again — to a sickle cell treatment that requires editing a ...

It’s the first part of what the company describes will grow to become a multimodal suite for biopharma researchers that will ...

Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy that combines the precision of monoclonal antibodies with the potency of ...

A research team, affiliated with UNIST has developed nanoparticles that effectively treat acute myeloid leukemia (AML), ...

DelveInsight's 'JAK Inhibitors Pipeline Insight 2024' report provides comprehensive global coverage of pipeline JAK ...

Gov. Kathy Hochul on Tuesday announced a $150 million investment in the new state-of-the-art therapy hub to be built on ...

The bioreactors market is expected to grow at 12.6% CAGR from 2024 to 2030. It is expected to reach above USD 24.24 billion by 2030 from USD 10.56 billion in 2023. Get the PDF Sample Copy of this ...